Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

Show other versions (2)

Background: Evaluating the long term benefit of therapy in multiple sclerosis (MS) is challenging. Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established. Methods: In a patie...

Bibliografske podrobnosti
Main Authors:	Goodin, D, Traboulsee, A, Knappertz, V, Reder, A, Li, D, Langdon, D, Wolf, C, Beckmann, K, Konieczny, A, Ebers, G
Format:	Journal article
Izdano:	2012

Podobne knjige/članki

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
od: Goodin, D, et al.
Izdano: (2012)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
od: Goodin, D, et al.
Izdano: (2012)

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
od: Goodin, D, et al.
Izdano: (2012)

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
od: Goodin, D, et al.
Izdano: (2012)

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
od: Ebers, G, et al.
Izdano: (2009)

Mortality in patients with multiple sclerosis.
od: Scalfari, A, et al.
Izdano: (2013)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
od: Ebers, G, et al.
Izdano: (2010)

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
od: Ebers, G, et al.
Izdano: (2011)

The final results of the interferon beta-1b 16-year long-term follow-up study
od: Ebers, G, et al.
Izdano: (2006)

The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes
od: Reder, A, et al.
Izdano: (2008)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
od: Reder, A, et al.
Izdano: (2010)

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study
od: Langdon, D, et al.
Izdano: (2007)

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
od: Douglas S Goodin, et al.
Izdano: (2011-01-01)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
od: Ebers, G, et al.
Izdano: (2005)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
od: Ebers, G, et al.
Izdano: (2004)

Causes of death among commercially insured multiple sclerosis patients in the United States.
od: Douglas S Goodin, et al.
Izdano: (2014-01-01)

Treatment of multiple sclerosis with interferon beta-1b - Reply
od: Sibley, W, et al.
Izdano: (1997)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
od: Sibley, W, et al.
Izdano: (1994)

Interferons in relapsing remitting multiple sclerosis.
od: Goodin, D
Izdano: (2003)

Cause of death in MS: Longterm follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study (BMJ Open (2012) 2 (e001972))
od: Goodin, D, et al.
Izdano: (2013)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
od: Petkau, A, et al.
Izdano: (2004)

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
od: Colin J. Ross, et al.
Izdano: (2017-05-01)

Systemic interferon alfa in multiple sclerosis.
od: Weinshenker, BG, et al.
Izdano: (1989)

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis
od: Ebers, G, et al.
Izdano: (1997)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
od: Filippini, G, et al.
Izdano: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
od: Filippini, G, et al.
Izdano: (2003)

Age and disability accumulation in multiple sclerosis.
od: Scalfari, A, et al.
Izdano: (2011)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
od: Paul I. Creeke, et al.
Izdano: (2013-01-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
od: Ebers, G, et al.
Izdano: (1998)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
od: Filippini, G, et al.
Izdano: (2003)

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection
od: Xuan Feng, et al.
Izdano: (2019-11-01)

The evolution of interferon therapy in multiple sclerosis
od: O. V. Boyko, et al.
Izdano: (2023-08-01)

Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis
od: V. Byrnes, et al.
Izdano: (2006-01-01)

Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy
od: A. D. Kukushkina, et al.
Izdano: (2024-08-01)

Association of smoking with risk of multiple sclerosis: a population-based study.
od: Ramagopalan, S, et al.
Izdano: (2013)

Association of smoking with risk of multiple sclerosis: A population-based study
od: Ramagopalan, S, et al.
Izdano: (2013)

Adherence to interferon β treatment in Kosovan multiple sclerosis registry
od: Blerim Myftiu, et al.
Izdano: (2024-01-01)

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN
od: L. M. Kuzenkova, et al.
Izdano: (2013-09-01)

Interferon beta treatment of multiple sclerosis.
od: Markovitz, D
Izdano: (1994)

CLINICALLY ISOLATED SYNDROME IN CHILDREN AND ADOLESCENTS — RISK FACTORS FOR MULTIPLE SCLEROSIS AND PROSPECTS OF USING INTRAMUSCULAR INTERFERON β-1A
od: O.V. Bykova, et al.
Izdano: (2010-05-01)